Researchers Map Pathways to Protective Antibodies for an HIV Vaccine
The findings advance progress toward HIV vaccine design
.jpg)
Contact
DURHAM, N.C. – A Duke Health-led research team has described both the pathway of HIV protective antibody development and a synthetic HIV outer envelope mimic that has the potential to induce the antibodies with vaccination.
“A goal for an HIV-1 vaccine is to induce broadly neutralizing antibodies,” said senior author Barton F. Haynes, M.D., director of the Duke Human Vaccine Institute (DHVI). “One strategy for the induction of these desirable antibodies is to find a way to develop a small portion of the envelope’s structure that these desired antibodies recognize – something we have now shown is possible.”
In the first of two papers published online March 15 in Science Translational Medicine, Haynes and colleagues – including lead author Mattia Bonsignori, M.D. of DHVI -- traced a series of events that led to the development of broadly neutralizing antibodies in an HIV infected person over the course of five years.
The researchers found that the infected person’s immune system responded to the virus with unusual, cooperative efforts between different B-cell lineages to induce broadly neutralizing antibodies. The antibody development process also involved acquisition of a rare genetic change critical for protective antibody activity.
In a second paper in the same edition of Science Translational Medicine, a team at Memorial Sloan Kettering Cancer Center, led by Samuel Danishefsky, Ph.D., used that blueprint to build a synthetic molecule that would mimic the HIV site targeted in infection. They also tested if the molecule could induce similar antibodies in the vaccination of a non-human primate.
The immunogen mimics a precise region of the virus where certain broadly neutralizing antibodies bind to generate an immune attack. The synthetic immunogen precisely mimics this site, and in non-human primate vaccination studies, can induce antibodies to this critical position.
The researchers at Duke, including lead author S. Munir Alam, Ph.D., report that the synthetic mimic induced antibodies targeted at the site much more quickly than what was observed in the original HIV-infected person.
“We have known that there is an Achilles’ heel on the envelope of the virus that the right kind of antibodies target,” Haynes said. “There is not just one spot, but several. An effective vaccine would need to target more than one of them to assure that the immune system is equipped with the weapons it needs to fight the virus through all of its mutations.”
A third study from the DHVI, published Feb. 28 in the journal Cell Reports, demonstrated that macaques could indeed be vaccinated with an envelope of HIV and made antibodies to envelope sugar molecules. The researchers, led by Kevin O. Saunders, Ph.D., immunized macaques over a three-year period, and found that after this long duration of immunization, macaques made antibodies targeted at a broadly neutralizing antibody binding site containing sugars.
Haynes said all three studies support the concept of designing vaccine candidates that mimic critical regions of HIV. He said the goal is to combine all multiple HIV components that elicit the protective antibodies into one vaccine that could be tested in humans.
In the first study, Haynes, Bonsignori and Alam were joined by R. Ryan Meyerhoff, Todd Bradley, Kevin Wiehe, Kwan-Ki Hwang, Kevin O. Saunders, Ruijun Zhang, Morgan A. Gladden, Anthony Monroe, Amit Kumar, Shi-Mao Xia, Melissa Cooper, Garnett Kelsoe, Wilton B. Williams, David C. Montefiori, Ashley Trama, Hua-Xin Liao, M. Anthony Moody and Feng Gao of Duke; Edward F. Kreider, George M. Shaw and Beatrice H. Hahn at the University of Pennsylvania; Daniela Fera, Brendan W. Pier, Claudia A. Jette and Stephen C. Harrison of Harvard University; Baptiste Aussedat, William E. Walkowicz and Samuel J. Danishefsky of Sloan-Kettering Institute of Cancer Research; Mark K. Louder, Krisha McKee, Robert T. Bailer and John R. Mascola at the National Institutes of Allergy and Infectious Diseases; Lynn Morris of the National Institute of Communicable Disease, Johannesburg, South Africa; John Kappes, of the University of Alabama at Birmingham; Kshitij Wagh, Peter T. Hraber and Bette T. Korber of Los Alamos National Laboratory; Gift Kamanga of Kamuzu Central Hospital, Lilongwe, Malawi; Myron S. Cohen of the University of North Carolina at Chapel Hill; Thomas B. Kepler of Boston University.
The study was funded by the National Institutes of Health through the National Institute of Allergy and Infectious Diseases (R01-AI120801, UM1-AI100645, 1-F32-AI116355-01, AI112426, AI122982-0) and the Medical Scientist Training Program (T32GM007171).
Along with Haynes, Alam and Bonsignori, the second study authors from Duke include Meyerhoff, Saunders, Moody, Montefiori, Wiehe, Liao, Kara Anasti, Lawrence Armand, Robert Parks, Laura Sutherland, Richard Scearce, Tarra Von Holle and Amanda Eaton; along with Baptiste Aussedat, Yusuf Vohra, William E. Walkowicz, Peter K. Park, Alberto Fernández-Tejada and Samuel Danishefsky of Memorial Sloan Kettering Cancer Center; Evan M. Cale, Nathan A. Radakovich, M. Gordon Joyce, Marie Pancera, Aliaksandr Druz, Ivelin S. Georgiev, Mark Louder, Robert T. Bailer, Peter D. Kwong and John R. Mascola of The National Institute of Allergy and Infectious Diseases; Joseph Sodroski of Harvard Medical School; Lynn Morris and Salim S. Abdool-Karim of National Institute of Communicable Diseases, Johannesburg, South Africa; Myron Cohen of the University of North Carolina at Chapel Hill; Sampa Santra of Beth Israel Deaconess Medical Center; Thomas B. Kepler of Boston University School of Medicine; and Christopher Fox and Steven G. Reed of Infectious Disease Research Institute.
The study received funding from the National Institutes of Health through the National Institute of Allergy and Infectious Diseases (UM-1 AI100645, R01 AI120801-01, F30-AI122982-0) and the Medical Scientist Training Program (T32GM007171).